Portosystemic Shunt

A portosystemic shunt (PSS) is an abnormal vascular connection that allows blood from the portal venous system to bypass the liver and enter the systemic circulation directly. This congenital or acquired anomaly results in the diversion of nutrient-rich, toxin-laden blood away from the hepatic parenchyma, leading to a constellation of clinical signs primarily related to hepatic encephalopathy, hypoglycemia, and failure to thrive. Congenital shunts are typically single, extrahepatic (in small breeds) or intrahepatic (in large breeds), while acquired shunts are multiple, extrahepatic, and develop secondary to portal hypertension. The shunt may be classified as intrahepatic (within the liver parenchyma) or extrahepatic (outside the liver), and as congenital or acquired. The clinical presentation varies from asymptomatic to severe neurological dysfunction, and the condition is a common cause of hepatic disease in young dogs and cats.

The etiology of portosystemic shunts is primarily congenital, resulting from abnormal embryonic development of the venous system. In dogs, a single congenital shunt is most common, with extrahepatic shunts typically connecting the portal vein or its tributaries (e.g., splenic, gastric, cranial mesenteric veins) to the caudal vena cava or azygos vein. Intrahepatic shunts often involve a patent ductus venosus, a fetal vessel that normally closes after birth. The exact cause of congenital shunt formation is unknown but is likely multifactorial, involving genetic predisposition and possibly environmental factors during fetal development. Acquired shunts are secondary to chronic portal hypertension, which can result from hepatic fibrosis, cirrhosis, or other causes of increased portal venous resistance. These shunts are usually multiple, tortuous, and extrahepatic, and they develop as a compensatory mechanism to decompress the portal system. In some cases, acquired shunts may be iatrogenic, following surgical attenuation of a congenital shunt that leads to persistent portal hypertension.

Portosystemic shunts are most commonly diagnosed in young dogs and cats, with a median age of 1-2 years at presentation. Congenital shunts are more frequent in purebred dogs, with a higher incidence in small breeds such as Yorkshire Terriers, Maltese, Poodles, Shih Tzus, and Dachshunds for extrahepatic shunts, and large breeds such as Irish Wolfhounds, Golden Retrievers, and Labrador Retrievers for intrahepatic shunts. In cats, congenital shunts are less common but are seen in breeds like Persians and Himalayans. There is no strong sex predilection, though some studies suggest a slight male predominance in certain breeds. Acquired shunts are more common in older animals with chronic liver disease, and the incidence is higher in dogs with cirrhosis. Geographic variation is not significant, but the condition is more frequently diagnosed in regions with a high prevalence of purebred dogs. The overall incidence of congenital PSS is estimated at 0.05-0.1% of the canine population, but it may be higher in predisposed breeds.

The pathophysiology of portosystemic shunts revolves around the shunting of portal blood away from the liver, leading to a loss of hepatic first-pass metabolism. This results in the accumulation of neurotoxic substances, particularly ammonia, in the systemic circulation. Ammonia is produced by bacterial fermentation of proteins in the gastrointestinal tract and is normally converted to urea in the liver via the urea cycle. When portal blood bypasses the liver, ammonia and other toxins (e.g., mercaptans, short-chain fatty acids, aromatic amino acids) enter the systemic circulation, causing hepatic encephalopathy. The liver also receives less hepatotrophic factors (e.g., insulin, glucagon) from the portal blood, leading to hepatic atrophy and impaired synthetic function. This results in decreased production of albumin, clotting factors, and urea, and altered glucose metabolism, predisposing to hypoglycemia. Additionally, the shunting of blood away from the liver reduces hepatic clearance of drugs and toxins, increasing the risk of drug toxicity. The clinical signs of hepatic encephalopathy are exacerbated by high-protein meals, gastrointestinal bleeding, constipation, and metabolic alkalosis, which increase ammonia production or absorption. Over time, chronic shunting can lead to progressive hepatic insufficiency and, in cases of acquired shunts, portal hypertension and ascites.

Predisposing factors for congenital portosystemic shunts include genetic predisposition, with certain breeds having a higher risk due to inherited traits. For example, Yorkshire Terriers and Irish Wolfhounds have a known familial tendency. Age is a significant factor, as congenital shunts typically manifest in young animals. Sex may play a role in some breeds, but the evidence is inconsistent. For acquired shunts, the primary predisposing factor is chronic liver disease leading to portal hypertension, such as cirrhosis, hepatic fibrosis, or chronic hepatitis. Other factors that may contribute to the development of acquired shunts include congenital hepatic fibrosis, portal vein hypoplasia, and arteriovenous fistulas. Environmental factors, such as diet, may influence the severity of clinical signs but are not direct causes. Concurrent conditions that increase intra-abdominal pressure or portal blood flow, such as pregnancy or obesity, may exacerbate the clinical signs. Additionally, certain medications that increase ammonia production or impair hepatic function may unmask latent shunts.

Clinical signs of portosystemic shunts are highly variable and often intermittent. The most common presentation is in young animals with a history of poor growth, lethargy, and neurological signs. Neurological signs of hepatic encephalopathy include depression, disorientation, circling, head pressing, ataxia, blindness, seizures, and coma. These signs may be precipitated by high-protein meals, gastrointestinal bleeding, or stress. Gastrointestinal signs include vomiting, diarrhea, anorexia, and ptyalism (especially in cats). Urinary signs, such as stranguria, hematuria, and pollakiuria, may occur due to ammonium urate urolithiasis. Physical examination may reveal a small, poorly developed animal with a distended abdomen (due to hepatomegaly or ascites in acquired cases), and a small liver on palpation. In some cases, a palpable abdominal mass may be felt if the shunt is large. Other findings include fever, icterus (in advanced cases), and signs of coagulopathy (e.g., petechiae, ecchymoses). In cats, a classic sign is excessive salivation and intermittent blindness. Chronic cases may show signs of hepatic fibrosis, such as ascites and peripheral edema, particularly in acquired shunts.

Differential diagnoses for portosystemic shunts include other causes of hepatic encephalopathy, such as acute hepatic failure (e.g., due to toxins, infections, or drugs), chronic hepatitis, cirrhosis, and hepatic neoplasia. Other metabolic diseases that can cause neurological signs include hypoglycemia (e.g., insulinoma, sepsis), hypocalcemia, and urea cycle enzyme deficiencies. Gastrointestinal diseases that cause vomiting and diarrhea, such as inflammatory bowel disease, parasitic infections, and dietary indiscretion, should also be considered. Urinary tract diseases, such as bacterial cystitis, urolithiasis, and neoplasia, may mimic the urinary signs. In young animals, congenital portosystemic shunts must be differentiated from other congenital hepatic vascular anomalies, such as microvascular dysplasia (hepatic microvascular dysplasia) and portal vein hypoplasia. Additionally, primary neurological disorders (e.g., epilepsy, hydrocephalus, encephalitis) and toxicities (e.g., lead poisoning, ethylene glycol) should be ruled out. Diagnostic tests, including liver function tests, bile acid stimulation test, and imaging, are essential to differentiate these conditions.

The diagnostic algorithm for portosystemic shunts begins with a thorough history and physical examination, focusing on young animals with compatible clinical signs. Initial laboratory tests include a complete blood count, serum biochemistry profile, and urinalysis. Key findings include microcytosis, low blood urea nitrogen (BUN), low albumin, low cholesterol, and low glucose. Liver enzyme activities may be normal or mildly elevated. Urinalysis may reveal ammonium biurate crystals. The next step is a serum bile acid stimulation test, which is the most sensitive and specific test for hepatic function. Fasting and 2-hour postprandial bile acid concentrations are measured; values above 25-30 µmol/L are strongly suggestive of a shunt. If bile acids are elevated, abdominal ultrasonography is performed to identify the shunt. Ultrasonography can often visualize the anomalous vessel and assess liver size. Doppler ultrasound can confirm the direction of blood flow. If ultrasonography is inconclusive, advanced imaging such as computed tomography (CT) angiography or mesenteric portovenography is recommended. CT angiography is the gold standard for surgical planning, as it provides detailed three-dimensional anatomy of the shunt. In some cases, exploratory laparotomy with intraoperative mesenteric portography may be necessary. Liver biopsy may be performed to assess hepatic histopathology, especially in cases of suspected microvascular dysplasia.

Laboratory findings in portosystemic shunts are characteristic but not pathognomonic. On complete blood count, microcytosis (low mean corpuscular volume) is common due to iron deficiency, and target cells may be seen. Serum biochemistry often reveals low BUN (due to impaired urea synthesis), low albumin, low cholesterol, and low glucose. Liver enzyme activities (ALT, AST, ALP) may be normal or mildly elevated. Bilirubin is usually normal unless there is concurrent hepatic disease. Serum ammonia levels may be elevated, but this test is less reliable than bile acids due to sample handling issues. Urinalysis may show low urine specific gravity (due to impaired concentrating ability), and ammonium biurate crystals may be present. In cases with urolithiasis, hematuria and pyuria may be seen. Blood gas analysis may reveal metabolic alkalosis, which can exacerbate hepatic encephalopathy. Specific biomarkers such as serum bile acids are the most useful; fasting bile acids > 25 µmol/L and postprandial > 30 µmol/L are highly suggestive of a shunt. Other biomarkers, such as serum ammonia, may be elevated but are less sensitive. Coagulation profiles may be prolonged due to decreased synthesis of clotting factors, but clinical bleeding is uncommon. In cats, low taurine levels may be seen, and in some cases, hyperbilirubinemia may occur.

Imaging is essential for the diagnosis and characterization of portosystemic shunts. Abdominal radiography may show a small liver (microhepatica) and, in some cases, renomegaly. However, radiography is not sensitive for detecting the shunt itself. Ultrasonography is the most commonly used imaging modality. On B-mode ultrasound, the liver may appear small and have a normal or slightly hyperechoic parenchyma. The shunt vessel may be visualized as an anomalous vessel connecting the portal system to the systemic circulation. Color Doppler and pulsed-wave Doppler can confirm the direction of blood flow (hepatofugal) and measure flow velocity. In extrahepatic shunts, the vessel is often seen as a tortuous vessel near the left kidney or caudal vena cava. Intrahepatic shunts may be seen as a large vessel within the liver parenchyma. Ultrasonography is operator-dependent and may miss small shunts. Computed tomography (CT) angiography is the gold standard for surgical planning. It provides detailed three-dimensional images of the vascular anatomy, allowing precise identification of the shunt type, location, and number. CT is particularly useful for intrahepatic shunts, which are difficult to visualize on ultrasound. Magnetic resonance imaging (MRI) is less commonly used but can also delineate vascular anatomy. Mesenteric portovenography, performed during surgery or via a catheter, can confirm the presence of a shunt and measure portal pressures. This is often done intraoperatively to guide surgical attenuation.

Cytology and histopathology are not typically used for the primary diagnosis of portosystemic shunts, but they may be performed to assess hepatic changes. Fine-needle aspiration of the liver may show hepatocytes with vacuolar changes, but this is nonspecific. Liver biopsy is more informative. Histopathological findings in congenital shunts include hepatic atrophy, with small hepatocytes and narrowed hepatic cords. There may be a paucity of portal veins, and the portal triads may be inconspicuous. In acquired shunts, there is evidence of chronic liver disease, such as fibrosis, nodular regeneration, and bile duct hyperplasia. Special stains, such as Masson's trichrome, can highlight fibrosis. In cases of microvascular dysplasia, histopathology may show abnormal small vessels within the hepatic acini. Liver biopsy is also useful to rule out other hepatic diseases, such as hepatitis or neoplasia. However, biopsy is not always necessary if imaging confirms a shunt, and it carries a risk of bleeding, especially in animals with coagulopathy.

Treatment of portosystemic shunts involves both medical management and surgical correction. Medical therapy is aimed at controlling clinical signs and stabilizing the patient before surgery. The primary goals are to reduce ammonia production and absorption, manage hepatic encephalopathy, and provide nutritional support. Dietary management involves feeding a high-quality, highly digestible protein-restricted diet, supplemented with soluble fiber (e.g., psyllium) to promote intestinal transit and reduce ammonia absorption. Lactulose (0.5-1 mL/kg PO q8h) is used to acidify the colonic contents and trap ammonia. Antibiotics such as neomycin (20 mg/kg PO q8h) or metronidazole (7.5-10 mg/kg PO q12h) are used to reduce ammonia-producing bacteria in the colon. In cases of acute hepatic encephalopathy, intravenous fluids with dextrose, potassium supplementation, and lactulose enemas may be necessary. Seizures may be controlled with levetiracetam (20 mg/kg IV or PO q8h) or other anticonvulsants. Surgical attenuation is the definitive treatment for congenital shunts. The goal is to gradually occlude the shunt vessel to allow the liver to regenerate and restore normal portal blood flow. This can be done via open surgery or minimally invasive techniques (e.g., laparoscopic or interventional radiology). In cases where complete attenuation is not possible, partial ligation or placement of an ameroid constrictor or cellophane band may be performed. Postoperative management includes monitoring for portal hypertension, which can cause ascites, abdominal pain, and seizures. Medical management may be continued postoperatively until the liver has regenerated. For acquired shunts, treatment is primarily medical, focusing on managing the underlying liver disease and portal hypertension. Surgical attenuation is not recommended for acquired shunts due to the risk of worsening portal hypertension.

The prognosis for portosystemic shunts depends on the type, severity, and treatment. For congenital shunts, surgical attenuation offers a good to excellent prognosis, with a reported success rate of 70-90% in dogs and cats. Most animals show significant improvement in clinical signs within weeks to months after surgery. The prognosis is better for extrahepatic shunts than for intrahepatic shunts, which are more technically challenging to correct. Complete attenuation is associated with a better long-term outcome than partial attenuation. However, some animals may require continued medical management even after surgery. The prognosis for acquired shunts is guarded, as they are associated with chronic liver disease and portal hypertension. Medical management can improve quality of life but is not curative. Negative prognostic indicators include the presence of severe hepatic encephalopathy, coagulopathy, and concurrent hepatic fibrosis. The mortality rate for surgical attenuation is approximately 5-10%, with most deaths occurring due to postoperative complications such as portal hypertension or seizures. Long-term survival is possible, with many animals living for years after successful surgery.

Follow-up care for portosystemic shunts is essential to monitor recovery and detect complications. After surgical attenuation, patients should be re-evaluated at 1, 3, 6, and 12 months postoperatively, and then annually. At each visit, a physical examination, serum biochemistry profile, and bile acid stimulation test should be performed. Bile acids should gradually decrease to normal levels as the liver regenerates. Imaging, such as ultrasound or CT, may be repeated to assess shunt closure and liver size. In cases of partial attenuation, serial bile acid measurements can help determine if further intervention is needed. Medical management should be tapered gradually as clinical signs improve. Dietary modifications may be continued for several months or indefinitely, depending on the degree of hepatic recovery. Owners should be educated to monitor for signs of portal hypertension, such as abdominal distension, vomiting, or seizures, and to seek immediate veterinary care if these occur. For animals managed medically, follow-up is more frequent, with re-checks every 1-3 months initially, then every 6 months. Long-term monitoring of liver function and quality of life is important.

Clinical pearls: 1) Always consider a portosystemic shunt in a young dog or cat with a history of poor growth, intermittent neurological signs, and ammonium biurate crystalluria. 2) Serum bile acid stimulation test is the most reliable screening test; fasting and postprandial samples are essential. 3) Microcytosis with normal iron stores is a classic hematologic finding. 4) Ultrasonography is a valuable diagnostic tool, but a negative ultrasound does not rule out a shunt; CT angiography is the gold standard. 5) Medical management is crucial for stabilizing patients before surgery; lactulose and a low-protein diet are the mainstays. 6) Surgical attenuation should be performed by an experienced surgeon, and intraoperative portography is helpful to guide the procedure. Pitfalls: 1) Do not rely on serum ammonia levels alone, as they are labile and can be falsely normal. 2) Avoid using diazepam for seizures in hepatic encephalopathy, as it may worsen encephalopathy; use levetiracetam instead. 3) Do not perform a liver biopsy without checking coagulation status, as these patients may have a bleeding tendency. 4) Be cautious with drugs that require hepatic metabolism; dose adjustments may be necessary. 5) Do not overlook the possibility of multiple shunts or concurrent microvascular dysplasia, which may affect surgical planning and prognosis.

Medical management of portosystemic shunts focuses on reducing ammonia production and absorption. Lactulose: 0.5-1 mL/kg PO q8h, titrated to produce 2-3 soft stools per day. For acute encephalopathy, lactulose can be administered as a retention enema (20-30 mL diluted with warm water) q6-8h. Antibiotics: Neomycin (20 mg/kg PO q8h) or metronidazole (7.5-10 mg/kg PO q12h) for 7-14 days, or long-term in some cases. Amoxicillin (22 mg/kg PO q12h) may be used as an alternative. For seizures, levetiracetam (20 mg/kg IV or PO q8h) is preferred; phenobarbital (2.5-5 mg/kg PO q12h) may be used but requires careful monitoring. For hypoglycemia, dextrose supplementation (2.5-5% in IV fluids) is necessary. In cases of urolithiasis, allopurinol (10 mg/kg PO q12h) may be used to prevent urate stone formation, but it is not a primary treatment. For portal hypertension postoperatively, management may include furosemide (1-2 mg/kg IV or PO q12h) and spironolactone (1-2 mg/kg PO q12h) for ascites. In cases of coagulopathy, vitamin K1 (0.5-1.5 mg/kg SC or PO q12h) may be administered. All dosages should be adjusted based on renal and hepatic function, and drug interactions should be considered, especially with drugs that are highly protein-bound or hepatically metabolized.

Evidence-based literature on portosystemic shunts includes several key studies and consensus statements. The ACVIM consensus statement on the diagnosis and treatment of portosystemic shunts (2014) provides guidelines for diagnosis and management. Studies have shown that surgical attenuation of congenital extrahepatic shunts results in excellent outcomes, with resolution of clinical signs in 80-90% of cases. A study by Tisdall et al. (2000) reported a 90% success rate with ameroid constrictor placement. For intrahepatic shunts, outcomes are more variable, with success rates of 60-80% depending on the technique. Medical management alone is associated with a poorer long-term prognosis, with a median survival time of 1-2 years. A study by Watson and Herrtage (1998) found that dogs treated medically had a median survival of 1.5 years, while surgically treated dogs had a median survival of 5 years. Recent advances in interventional radiology, such as transvenous coil embolization, have shown promising results with lower morbidity. A study by Weisse et al. (2014) reported successful closure in 80% of cases with minimal complications. Overall, the evidence supports early surgical intervention for congenital shunts, with medical management as a bridge to surgery or for non-surgical candidates.